A Clinical Case of Successful Treatment of HER2-Low Disseminated Breast Cancer with Trastuzumab Deruxtecan

##article.numberofdownloads## 201

##article.numberofviews## 491

Keywords

argeted anti-HER2 therapy
trastuzumab
Trastuzumab deruxtecan
hormone-positive metastatic breast cancer
HER2-Low

How to Cite

Panferova, E., Tepikina, G., Baryshnikov, E., Panferova, E., Murzin, A., Prokhorenko, A., Chupakhin, I., & Klemesheva, E. (2023). A Clinical Case of Successful Treatment of HER2-Low Disseminated Breast Cancer with Trastuzumab Deruxtecan. Voprosy Onkologii, 69(4), 757–760. https://doi.org/10.37469/0507-3758-2023-69-4-757-760

Abstract

Trastuzumab-based anti-HER2 therapy is the standard treatment for patients with HER2-positive tumors. Implementation of targeted therapy has significantly improved the prognosis and quality of life for patients with HER2-positive breast cancer (HER2+).

In this clinical case, we present the first experience in the Irkutsk region of effectively treating a patient with progressive disseminated hormone receptor-positive breast cancer with low HER2 expression (HER2-Low) using the drug trastuzumab deruxtecan. The patient had nearly exhausted all possibilities of anti-tumor drug treatment. Similar efficacy of trastuzumab deruxtecan has been demonstrated in a study called DESTINY-Breast04 (NCT03734029) involving a similar group of patients.

https://doi.org/10.37469/0507-3758-2023-69-4-757-760

##article.numberofdownloads## 201

##article.numberofviews## 491

pdf (Русский)

References

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660.

Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2022:252 [Kaprin AD, Starinsky VV, Shakhzadova AO, eds. Malignant neoplasms in Russia in 2021 (morbidity and mortality). Moscow: MCRI PA Herzen - branch FSBU «NMRC Radiology» of Ministry of Health of Russia. 2022:252 (In Russ.)].

Владимирова Л.Ю., Сторожакова А.Э., Снежко Т.А., и др. Гормоноположительный HER2-негативный метастатический рак молочной железы: принятие решений в реальной клинической практике. Южно-российский онкологический журнал. 2020;1(2):46-51 [Vladimirova LYu, Storozhakova AE, Snezhko TA, et al. Hormone-positive HER2-negative metastatic breast cancer: decision making in real clinical practice. South Russian Journal of Cancer. 2020;1(2):46-51 (In Russ.)]. doi:10.37748/2687-0533-2020-1-2-6.

Early Breast Cancer Trialists’ Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol. 2021;22(8):1139-1150. doi:10.1016/S1470-2045(21)00288-6.

Cortés J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143-1154. doi:10.1056/NEJMoa2115022.

Lee J, Park YH. Trastuzumab deruxtecan for HER2+ advanced breast cancer. Future Oncol. 2022;18(1):7-19. doi:10.2217/fon-2021-0550.

Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9-20. doi:10.1056/NEJMoa2203690.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.